Recommendation of the President – Prevenar 20
On 15 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 48/2026 onthe inclusion of the medicinal product Prevenar 20 (a 20-valent, adsorbed, conjugated pneumococcal polysaccharide vaccine) in the reimbursement program for the indication: prevention of pneumococcal infections in adults aged 65 and older